<p>隨着 2026 年的開始，亞洲市場正在應對一個複雜的環境，主要指數表現不一，對經濟復甦持謹慎樂觀態度。在這種氣候下，識別被低估的股票對於希望利用潛在增長機會的投資者來説，可以是一項戰略性舉措，特別是那些被估計顯著低於其內在價值的股票。</p>
<h3>基於現金流的亞洲十大被低估股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>當前價格</strong></td>
<td><strong>公允價值（估計）</strong></td>
<td><strong>折扣（估計）</strong></td>
</tr>
<tr>
<td>西安國際醫療投資（SZSE:000516）</td>
<td>CN¥4.72</td>
<td>CN¥9.38</td>
<td>49.7%</td>
</tr>
<tr>
<td>廈門特寶生物科技（SHSE:688278）</td>
<td>CN¥83.40</td>
<td>CN¥162.39</td>
<td>48.6%</td>
</tr>
<tr>
<td>高樂生物（TSE:4974）</td>
<td>¥795.00</td>
<td>¥1579.24</td>
<td>49.7%</td>
</tr>
<tr>
<td>四川凱倫生物製藥（SEHK:6990）</td>
<td>HK$432.00</td>
<td>HK$851.22</td>
<td>49.2%</td>
</tr>
<tr>
<td>Plus Alpha Consulting Ltd（TSE:4071）</td>
<td>¥2332.00</td>
<td>¥4591.95</td>
<td>49.2%</td>
</tr>
<tr>
<td>Mobvista（SEHK:1860）</td>
<td>HK$15.43</td>
<td>HK$30.64</td>
<td>49.6%</td>
</tr>
<tr>
<td>美圖（SEHK:1357）</td>
<td>HK$7.59</td>
<td>HK$14.75</td>
<td>48.5%</td>
</tr>
<tr>
<td>Kuraray（TSE:3405）</td>
<td>¥1599.50</td>
<td>¥3167.05</td>
<td>49.5%</td>
</tr>
<tr>
<td>大巨人纖維服裝（TWSE:4441）</td>
<td>NT$234.50</td>
<td>NT$457.28</td>
<td>48.7%</td>
</tr>
<tr>
<td>CURVES HOLDINGS（TSE:7085）</td>
<td>¥794.00</td>
<td>¥1582.86</td>
<td>49.8%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們基於現金流的 260 只被低估的亞洲股票的完整列表。</p>
<p>我們將查看我們篩選工具中的一些最佳選擇。</p>
<h2>三星電子（KOSE:A005930）</h2>
<p><strong>概述：</strong> 三星電子有限公司在消費電子、信息技術和移動通信以及設備解決方案領域全球運營，市值為₩903.85 萬億。</p>
<p><strong>運營：</strong> 公司的收入部分包括設備體驗（DX）為₩184.19 萬億，設備解決方案（DS）為₩116.22 萬億，SDC 為₩28.47 億，Harman 為₩15.13 億。</p>
<p><strong>公允價值折扣估計：</strong> 43.6%</p>
<p>三星電子的交易價格為₩138,100，顯著低於其估計的公允價值₩244,763.67。儘管預計年收入增長 12.3%——超過韓國市場的 11.4%——但其股本回報率預計將保持在 10.4% 的低位。預計未來三年盈利將顯著增長，年增長率超過 40%，超過更廣泛市場的 31.8% 增長率。近期的產品創新和戰略合作增強了其綜合生態系統和人工智能能力。</p>
<ul>
<li>根據我們的盈利增長報告，三星電子可能準備擴張。</li>
<li>點擊探索我們在三星電子資產負債表健康報告中的詳細分析。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/23ed9cb7-f310-45a5-a486-e97223e0eeac/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/23ed9cb7-f310-45a5-a486-e97223e0eeac/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>KOSE:A005930 截至 2026 年 1 月的折現現金流</p>
<h2>四川凱倫生物製藥（SEHK:6990）</h2>
<p><strong>概述：</strong> 四川凱倫生物製藥有限公司是一家生物製藥公司，專注於腫瘤學和免疫學的新藥研究、開發、生產和商業化，市值約為 HK$100.74 億。</p>
<p><strong>運營：</strong> 該公司通過其製藥部門產生約 CN¥15 億的收入，其中包括腫瘤學和免疫學的新藥。</p>
<p><strong>公允價值折扣估計：</strong> 49.2%</p>
<p>四川凱倫生物製藥的交易價格為 HK$432，遠低於其估計的公允價值 HK$851.22。預計該公司的收入將以 32.1% 的年增長率顯著增長，超過香港市場的 8.3% 增長率。預計在三年內實現盈利，股本回報率預計高達 27.5%。近期在抗體藥物偶聯物方面的突破和戰略合作可能會增強其財務前景，並加快在中國的產品審批。</p>
<ul>
<li>我們的盈利增長報告揭示了四川凱倫生物製藥未來結果顯著增長的潛力。</li>
<li>點擊這裏瞭解四川凱倫生物製藥的全面財務健康報告。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6f0d4402-5dd1-4a56-9456-4353239b7bb5/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6f0d4402-5dd1-4a56-9456-4353239b7bb5/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SEHK:6990 截至 2026 年 1 月的折現現金流</p>
<h2>武漢光電（SZSE:002414）</h2>
<p><strong>概述：</strong> 武漢光電有限公司設計、製造、營銷和銷售紅外熱成像探測器和模塊以及電光系統，市值為 CN¥68.93 億。</p>
<p><strong>運營：</strong> 武漢光電有限公司通過生產和分銷紅外熱成像探測器、模塊和電光系統在國內和國際市場上產生收入。</p>
<p><strong>公允價值折扣估計：</strong> 35.9%</p>
<p>武漢光電的交易價格為 CN¥16.14，顯著低於其估計的公允價值 CN¥25.18，表明其可能在現金流基礎上被低估。該公司表現出強勁的財務業績，2025 年前九個月收入達到 CNY 30.7 億，淨收入從去年同期的 CNY 5.02 億增加到 CNY 5.82 億。預測顯示年盈利增長超過 61%，超過中國市場的平均增長率。</p>
<ul>
<li>我們最近的增長報告提供了武漢光電業務前景的良好預測。</li>
<li>點擊這裏訪問我們的完整資產負債表健康報告，以瞭解武漢光電的動態。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6a0b0920-be46-4387-a40e-f0d75583886e/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6a0b0920-be46-4387-a40e-f0d75583886e/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SZSE:002414 截至 2026 年 1 月的折現現金流</p>
<h2>讓它發生</h2>
<ul>
<li>在這裏瀏覽 260 只基於現金流的被低估亞洲股票的完整庫存。</li>
<li>你是否已經投資於這些公司？利用 Simply Wall St 的投資組合，密切關注影響你投資的市場動態。</li>
<li>通過 Simply Wall St 解鎖知情投資的力量，這是你在全球股市中導航的免費指南。</li>
</ul>
<h2>考慮其他策略？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>通過提供可靠收入來源的穩健分紅股票來分散你的投資組合，以應對潛在的市場波動。</li>
<li>用顯示強勁增長潛力的公司來充實你的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
</ul>
<p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不構成財務建議。它不構成買入或賣出任何股票的推薦，也未考慮你的目標或財務狀況。</strong> 我們旨在為你提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

三星電子

特寶生物

<p>截至 2026 年，亞洲市場表現參差不齊，促使投資者尋求被低估的股票。值得關注的公司包括西安國際醫療投資、廈門特寶生物和四川凱倫生物科技，預計它們的內在價值顯著低於市場價格，折扣範圍在 48.5% 到 49.7% 之間。三星電子和武漢導熱紅外線也被提及，交易價格低於其公允價值，並預計將實現強勁的盈利增長。這些見解表明，隨着公司展現出良好的財務預測和增長潛力，亞洲市場存在潛在的投資機會</p>

<p>As 2026 begins, Asian markets are navigating a complex landscape marked by mixed performances across major indices and cautious optimism about economic recovery. In this climate, identifying undervalued stocks can be a strategic move for investors looking to capitalize on potential growth opportunities, particularly those estimated to be significantly below their intrinsic value.</p>
<div class="lb-trans"><p>隨着 2026 年的開始，亞洲市場正在應對一個複雜的環境，主要指數表現不一，對經濟復甦持謹慎樂觀態度。在這種氣候下，識別被低估的股票對於希望利用潛在增長機會的投資者來説，可以是一項戰略性舉措，特別是那些被估計顯著低於其內在價值的股票。</p>
</div><h3>Top 10 Undervalued Stocks Based On Cash Flows In Asia</h3>
<div class="lb-trans"><h3>基於現金流的亞洲十大被低估股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Current Price</strong></td>
<td><strong>Fair Value (Est)</strong></td>
<td><strong>Discount (Est)</strong></td>
</tr>
<tr>
<td>Xi'an International Medical Investment (SZSE:000516)</td>
<td>CN¥4.72</td>
<td>CN¥9.38</td>
<td>49.7%</td>
</tr>
<tr>
<td>Xiamen Amoytop Biotech (SHSE:688278)</td>
<td>CN¥83.40</td>
<td>CN¥162.39</td>
<td>48.6%</td>
</tr>
<tr>
<td>Takara Bio (TSE:4974)</td>
<td>¥795.00</td>
<td>¥1579.24</td>
<td>49.7%</td>
</tr>
<tr>
<td>Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990)</td>
<td>HK$432.00</td>
<td>HK$851.22</td>
<td>49.2%</td>
</tr>
<tr>
<td>Plus Alpha ConsultingLtd (TSE:4071)</td>
<td>¥2332.00</td>
<td>¥4591.95</td>
<td>49.2%</td>
</tr>
<tr>
<td>Mobvista (SEHK:1860)</td>
<td>HK$15.43</td>
<td>HK$30.64</td>
<td>49.6%</td>
</tr>
<tr>
<td>Meitu (SEHK:1357)</td>
<td>HK$7.59</td>
<td>HK$14.75</td>
<td>48.5%</td>
</tr>
<tr>
<td>Kuraray (TSE:3405)</td>
<td>¥1599.50</td>
<td>¥3167.05</td>
<td>49.5%</td>
</tr>
<tr>
<td>Great Giant Fibre Garment (TWSE:4441)</td>
<td>NT$234.50</td>
<td>NT$457.28</td>
<td>48.7%</td>
</tr>
<tr>
<td>CURVES HOLDINGS (TSE:7085)</td>
<td>¥794.00</td>
<td>¥1582.86</td>
<td>49.8%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>當前價格</strong></td>
<td><strong>公允價值（估計）</strong></td>
<td><strong>折扣（估計）</strong></td>
</tr>
<tr>
<td>西安國際醫療投資（SZSE:000516）</td>
<td>CN¥4.72</td>
<td>CN¥9.38</td>
<td>49.7%</td>
</tr>
<tr>
<td>廈門特寶生物科技（SHSE:688278）</td>
<td>CN¥83.40</td>
<td>CN¥162.39</td>
<td>48.6%</td>
</tr>
<tr>
<td>高樂生物（TSE:4974）</td>
<td>¥795.00</td>
<td>¥1579.24</td>
<td>49.7%</td>
</tr>
<tr>
<td>四川凱倫生物製藥（SEHK:6990）</td>
<td>HK$432.00</td>
<td>HK$851.22</td>
<td>49.2%</td>
</tr>
<tr>
<td>Plus Alpha Consulting Ltd（TSE:4071）</td>
<td>¥2332.00</td>
<td>¥4591.95</td>
<td>49.2%</td>
</tr>
<tr>
<td>Mobvista（SEHK:1860）</td>
<td>HK$15.43</td>
<td>HK$30.64</td>
<td>49.6%</td>
</tr>
<tr>
<td>美圖（SEHK:1357）</td>
<td>HK$7.59</td>
<td>HK$14.75</td>
<td>48.5%</td>
</tr>
<tr>
<td>Kuraray（TSE:3405）</td>
<td>¥1599.50</td>
<td>¥3167.05</td>
<td>49.5%</td>
</tr>
<tr>
<td>大巨人纖維服裝（TWSE:4441）</td>
<td>NT$234.50</td>
<td>NT$457.28</td>
<td>48.7%</td>
</tr>
<tr>
<td>CURVES HOLDINGS（TSE:7085）</td>
<td>¥794.00</td>
<td>¥1582.86</td>
<td>49.8%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 260 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們基於現金流的 260 只被低估的亞洲股票的完整列表。</p>
</div><p>We're going to check out a few of the best picks from our screener tool.</p>
<div class="lb-trans"><p>我們將查看我們篩選工具中的一些最佳選擇。</p>
</div><h2>Samsung Electronics (KOSE:A005930)</h2>
<div class="lb-trans"><h2>三星電子（KOSE:A005930）</h2>
</div><p><strong>Overview:</strong> Samsung Electronics Co., Ltd. operates globally in consumer electronics, information technology and mobile communications, and device solutions, with a market cap of ₩903.85 trillion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 三星電子有限公司在消費電子、信息技術和移動通信以及設備解決方案領域全球運營，市值為₩903.85 萬億。</p>
</div><p><strong>Operations:</strong> The company's revenue segments consist of Device Experience (DX) at ₩184.19 billion, Device Solutions (DS) at ₩116.22 billion, SDC at ₩28.47 million, and Harman at ₩15.13 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入部分包括設備體驗（DX）為₩184.19 萬億，設備解決方案（DS）為₩116.22 萬億，SDC 為₩28.47 億，Harman 為₩15.13 億。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 43.6%</p>
<div class="lb-trans"><p><strong>公允價值折扣估計：</strong> 43.6%</p>
</div><p>Samsung Electronics is trading at ₩138,100, significantly below its estimated fair value of ₩244,763.67. Despite a forecasted revenue growth of 12.3% annually—outpacing the Korean market's 11.4%—its Return on Equity is expected to remain low at 10.4%. Earnings are projected to grow significantly by over 40% annually in the next three years, surpassing the broader market's growth rate of 31.8%. Recent product innovations and strategic partnerships enhance its integrated ecosystem and AI capabilities.</p>
<div class="lb-trans"><p>三星電子的交易價格為₩138,100，顯著低於其估計的公允價值₩244,763.67。儘管預計年收入增長 12.3%——超過韓國市場的 11.4%——但其股本回報率預計將保持在 10.4% 的低位。預計未來三年盈利將顯著增長，年增長率超過 40%，超過更廣泛市場的 31.8% 增長率。近期的產品創新和戰略合作增強了其綜合生態系統和人工智能能力。</p>
</div><ul>
<li>According our earnings growth report, there's an indication that Samsung Electronics might be ready to expand.</li>
<li>Click to explore a detailed breakdown of our findings in Samsung Electronics' balance sheet health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>根據我們的盈利增長報告，三星電子可能準備擴張。</li>
<li>點擊探索我們在三星電子資產負債表健康報告中的詳細分析。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/23ed9cb7-f310-45a5-a486-e97223e0eeac/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/23ed9cb7-f310-45a5-a486-e97223e0eeac/chart/dcf?theme=light"/></p>
<p>KOSE:A005930 Discounted Cash Flow as at Jan 2026</p>
<div class="lb-trans"><p>KOSE:A005930 截至 2026 年 1 月的折現現金流</p>
</div><h2>Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990)</h2>
<div class="lb-trans"><h2>四川凱倫生物製藥（SEHK:6990）</h2>
</div><p><strong>Overview:</strong> Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company involved in the research, development, manufacturing, and commercialization of novel drugs focusing on oncology and immunology both in China and internationally, with a market cap of approximately HK$100.74 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 四川凱倫生物製藥有限公司是一家生物製藥公司，專注於腫瘤學和免疫學的新藥研究、開發、生產和商業化，市值約為 HK$100.74 億。</p>
</div><p><strong>Operations:</strong> The company generates revenue of approximately CN¥1.50 billion from its pharmaceuticals segment, which includes novel drugs in oncology and immunology.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司通過其製藥部門產生約 CN¥15 億的收入，其中包括腫瘤學和免疫學的新藥。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 49.2%</p>
<div class="lb-trans"><p><strong>公允價值折扣估計：</strong> 49.2%</p>
</div><p>Sichuan Kelun-Biotech Biopharmaceutical is trading at HK$432, well below its estimated fair value of HK$851.22. The company's revenue is projected to grow significantly at 32.1% annually, surpassing the Hong Kong market's growth rate of 8.3%. It is expected to become profitable within three years with a high Return on Equity forecasted at 27.5%. Recent breakthroughs in antibody-drug conjugates and strategic collaborations could bolster its financial outlook and expedite product approvals in China.</p>
<div class="lb-trans"><p>四川凱倫生物製藥的交易價格為 HK$432，遠低於其估計的公允價值 HK$851.22。預計該公司的收入將以 32.1% 的年增長率顯著增長，超過香港市場的 8.3% 增長率。預計在三年內實現盈利，股本回報率預計高達 27.5%。近期在抗體藥物偶聯物方面的突破和戰略合作可能會增強其財務前景，並加快在中國的產品審批。</p>
</div><ul>
<li>Our earnings growth report unveils the potential for significant increases in Sichuan Kelun-Biotech Biopharmaceutical's future results.</li>
<li>Navigate through the intricacies of Sichuan Kelun-Biotech Biopharmaceutical with our comprehensive financial health report here.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們的盈利增長報告揭示了四川凱倫生物製藥未來結果顯著增長的潛力。</li>
<li>點擊這裏瞭解四川凱倫生物製藥的全面財務健康報告。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6f0d4402-5dd1-4a56-9456-4353239b7bb5/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/6f0d4402-5dd1-4a56-9456-4353239b7bb5/chart/dcf?theme=light"/></p>
<p>SEHK:6990 Discounted Cash Flow as at Jan 2026</p>
<div class="lb-trans"><p>SEHK:6990 截至 2026 年 1 月的折現現金流</p>
</div><h2>Wuhan Guide Infrared (SZSE:002414)</h2>
<div class="lb-trans"><h2>武漢光電（SZSE:002414）</h2>
</div><p><strong>Overview:</strong> Wuhan Guide Infrared Co., Ltd. designs, manufactures, markets, and sells infrared thermal imaging detectors and modules as well as electro-optical systems both in China and internationally, with a market cap of CN¥68.93 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 武漢光電有限公司設計、製造、營銷和銷售紅外熱成像探測器和模塊以及電光系統，市值為 CN¥68.93 億。</p>
</div><p><strong>Operations:</strong> Wuhan Guide Infrared Co., Ltd. generates revenue through the production and distribution of infrared thermal imaging detectors, modules, and electro-optical systems across domestic and international markets.</p>
<div class="lb-trans"><p><strong>運營：</strong> 武漢光電有限公司通過生產和分銷紅外熱成像探測器、模塊和電光系統在國內和國際市場上產生收入。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 35.9%</p>
<div class="lb-trans"><p><strong>公允價值折扣估計：</strong> 35.9%</p>
</div><p>Wuhan Guide Infrared is trading at CN¥16.14, significantly below its estimated fair value of CN¥25.18, suggesting it may be undervalued based on cash flows. The company has shown strong financial performance, with revenue reaching CNY 3.07 billion for the first nine months of 2025 and net income increasing to CNY 581.94 million from CNY 50.21 million a year ago. Forecasts indicate robust annual earnings growth of over 61%, outpacing the Chinese market's average growth rate.</p>
<div class="lb-trans"><p>武漢光電的交易價格為 CN¥16.14，顯著低於其估計的公允價值 CN¥25.18，表明其可能在現金流基礎上被低估。該公司表現出強勁的財務業績，2025 年前九個月收入達到 CNY 30.7 億，淨收入從去年同期的 CNY 5.02 億增加到 CNY 5.82 億。預測顯示年盈利增長超過 61%，超過中國市場的平均增長率。</p>
</div><ul>
<li>Insights from our recent growth report point to a promising forecast for Wuhan Guide Infrared's business outlook.</li>
<li>Click here and access our complete balance sheet health report to understand the dynamics of Wuhan Guide Infrared.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們最近的增長報告提供了武漢光電業務前景的良好預測。</li>
<li>點擊這裏訪問我們的完整資產負債表健康報告，以瞭解武漢光電的動態。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6a0b0920-be46-4387-a40e-f0d75583886e/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/6a0b0920-be46-4387-a40e-f0d75583886e/chart/dcf?theme=light"/></p>
<p>SZSE:002414 Discounted Cash Flow as at Jan 2026</p>
<div class="lb-trans"><p>SZSE:002414 截至 2026 年 1 月的折現現金流</p>
</div><h2>Make It Happen</h2>
<div class="lb-trans"><h2>讓它發生</h2>
</div><ul>
<li>Navigate through the entire inventory of 260 Undervalued Asian Stocks Based On Cash Flows here.</li>
<li>Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.</li>
<li>Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏瀏覽 260 只基於現金流的被低估亞洲股票的完整庫存。</li>
<li>你是否已經投資於這些公司？利用 Simply Wall St 的投資組合，密切關注影響你投資的市場動態。</li>
<li>通過 Simply Wall St 解鎖知情投資的力量，這是你在全球股市中導航的免費指南。</li>
</ul>
</div><h2>Contemplating Other Strategies?</h2>
<div class="lb-trans"><h2>考慮其他策略？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>通過提供可靠收入來源的穩健分紅股票來分散你的投資組合，以應對潛在的市場波動。</li>
<li>用顯示強勁增長潛力的公司來充實你的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation.</strong> We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不構成財務建議。它不構成買入或賣出任何股票的推薦，也未考慮你的目標或財務狀況。</strong> 我們旨在為你提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

3 只亞洲股票被估計低於其內在價值 35.9% 至 49.2%